胸腺素α1与复合α干扰素融合蛋白的表达及其生物学活性

Expression and Activity Analysis of Interferonα-con and Thymosin-α1

实验旨在获得具有双重生物学活性的重组胸腺素α1(Thymosin alpha1,TM-α1)与复合α干扰素(IFNα-con)融合蛋白。选择大肠杆菌偏爱的密码子,将合成的TM-α1与IFNα-con编码序列构成的融和基因克隆至大肠杆菌表达载体pET-22b(+)、在宿主菌BL21(DE3)-Codon plus-RP-X中成功表达了可溶性融合蛋白(TM-α1-IFN-con)。表达量占总蛋白的20%以上。通过硫酸铵沉淀、疏水层析、阴离子交换层析、阳离子交换层析、分子筛层析后,产品纯度达到96%以上。采用细胞病变抑制法测定融合蛋白的抗病毒活性,采用细胞增殖实验检测融合蛋白对小鼠脾淋巴细胞增殖的影响。结果表明,融合蛋白的抗病毒活性优于市售的IFNα1b和IFNα2a。对小鼠脾淋巴细胞增殖的影响与市售的合成胸腺素α1相同。已有研究证实,该融合蛋白具有良好的体外抗HBV作用,其体外抗HBV活性比联合应用TM-α1和干扰素α强,且细胞毒性明显低于联合应用TM-α1和干扰素α。以上结果表明,通过大肠杆菌表达的可溶性融合蛋白(TM-α1-IFN-con),既具有良好的干扰素α抗病毒作用,也具有胸腺素α1促淋巴细胞增殖作用。

This study aimed to obtain recombinant fusion protein of thymosin alphal（TM-α1） and consensus IFNα （IFNα-con） which have bath TM-α1 and IFNα-con activities. The DNA sequence for the fusion protein was cloned into expression vector of pET-22b （＋） and expressed in BL21 （DE3）-Codon plus-RP-X. The expressed product （TM-α1-IFN-con） was soluble, and amounted to more than 20% in total proteins of E. coli. By precipitation of （NH4）2SO4, hydrophobic interaction chromatography （HIC, Phenyl Sepharose 6 Fast Flow）, anion-exchange chromatography （Q Sepharose Fast Flow）, cation-exchange chromatography （SP Sepharose Fast Flow） and gel filtration （Sephadex G-75）, it was purified to more than 96% purity. The activity of fusion protein for antivirus was tested by cytopathic-effect inhibition assay and activity for promoting lymphocyte proliferation was tested by cell proliferative assay. The activity for antivirus was higher than commercial IFNα1b and IFNα2a and activity for promoting lymphocyte proliferation was similar to commercial TM-α1. The fusion protein had better effect for anti-HBV in vitro, its effect was stronger than combination of IFNα and TM-α1 and cell toxicity was less than combination of IFNα and TM-α1. The above results show that it has effect bath antivirus of IFNα and promoting lymphocyte proliferation of the soluble fusion protein expressed in E. coli.